

Specialty Guideline Management

mifepristone-Korlym

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Korlym	mifepristone

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indications^{1,2}

Indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Limitations of Use:

Should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing's syndrome.

All other indications are considered experimental/investigational and not medically necessary.

Documentation

Submission of the following information is necessary to initiate the prior authorization review: pretreatment hemoglobin A1C level (for initial requests)

Coverage Criteria

Cushing's Syndrome/Disease¹⁻⁴

Authorization of 6 months may be granted for treatment of Cushing's syndrome/disease when all of the following criteria are met:

- Member has type 2 diabetes mellitus or glucose intolerance
- The requested drug is being prescribed to control hyperglycemia secondary to hypercortisolism
- Member has had surgery that was not curative OR member is not a candidate for surgery
- If the member is able to become pregnant, a negative pregnancy test is required before initiating therapy

Continuation of Therapy

Cushing's Syndrome/Disease¹⁻⁴

Authorization of 12 months may be granted if the member has achieved or maintained an adequate positive response, or there is improvement in signs and symptoms of the condition.

References

1. Korlym [package insert]. Menlo Park, CA: Corcept Therapeutics Incorporated; September 2024.
2. Mifepristone [package insert]. Menlo Park, CA: Corcept Therapeutics Incorporated; September 2024.
3. Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(8):2807-2831. doi:10.1210/jc.2015-1818
4. Fleseriu M, Auchus R, Bancos I, et al. Consensus on Diagnosis and Management of Cushing's Disease: A Guideline Update. Lancet Diabetes Endocrinol. 2021;9(12):847-875. doi:10.1016/S2213-8587(21)00235-7